MX2015002588A - Proteinas de fusion y metodos para tratar, prevenir o aliviar el dolor. - Google Patents

Proteinas de fusion y metodos para tratar, prevenir o aliviar el dolor.

Info

Publication number
MX2015002588A
MX2015002588A MX2015002588A MX2015002588A MX2015002588A MX 2015002588 A MX2015002588 A MX 2015002588A MX 2015002588 A MX2015002588 A MX 2015002588A MX 2015002588 A MX2015002588 A MX 2015002588A MX 2015002588 A MX2015002588 A MX 2015002588A
Authority
MX
Mexico
Prior art keywords
protease
amino acid
sensory afferent
nociceptive sensory
site
Prior art date
Application number
MX2015002588A
Other languages
English (en)
Other versions
MX369005B (es
Inventor
John Chaddock
Peter James
Keith Foster
Roger Kei Aoki
Lance Steward
Joseph Francis
Original Assignee
Syntaxin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntaxin Ltd filed Critical Syntaxin Ltd
Publication of MX2015002588A publication Critical patent/MX2015002588A/es
Publication of MX369005B publication Critical patent/MX369005B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21072—IgA-specific serine endopeptidase (3.4.21.72)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24068—Tentoxilysin (3.4.24.68), i.e. tetanus neurotoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24013—IgA-specific metalloendopeptidase (3.4.24.13)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Una proteína de fusión de polipéptido de cadena simple, que comprende: una proteasa no citotóxica, cuya proteasa es capaz de escindir una proteína del aparato de fusión exocítico de un aferente sensorial nociceptivo (por ejemplo, cadena L de neurotoxina clostridial o proteasa de IgA); una Porción de Selección de galanina que es capaz de unirse a un Sitio de Unión en el aferente sensorial nociceptivo, cuyo Sitio de Unión es capaz de experimentar endocitosis para ser incorporado en un endosoma dentro del aferente sensorial nociceptivo (por ejemplo, el receptor GALR1, GALR2, o GALR3); un sitio de escisión de proteasa en cuyo sitio la proteína de fusión se escinde por una proteasa, en donde el sitio de escisión de proteasa se ubica entre la proteasa no citotóxica y la Porción de Selección de galanina; un dominio de translocación que es capaz de transiocar la proteasa desde dentro de un endosoma, a través de la membrana endosomal y en el citosol del aferente sensorial nociceptivo (por ejemplo, el dominio HN de neurotoxina clostridial) ; un primer espaciador ubicado entre la proteasa no citotóxica y el sitio de escisión de proteasa, en donde el primer espaciador comprende una secuencia de aminoácidos de 4 a 25 residuos de aminoácidos; y un segundo espaciador ubicado entre la Porción de Selección de galanina y el dominio de translocación, en donde el segundo espaciador comprende una secuencia de aminoácidos de 4 a 35 residuos de aminoácidos. Las secuencias de ácido nucleico que codifican las proteínas de fusión de polipéptido, métodos para preparar las mismas y usos de los mismos también se describen (por ejemplo, para tratar, prevenir o aliviar el dolor).
MX2015002588A 2012-08-27 2013-08-27 Proteinas de fusión y usos de las mismas para tratar, prevenir o aliviar el dolor. MX369005B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/595,927 US20140056870A1 (en) 2012-08-27 2012-08-27 Fusion proteins
PCT/GB2013/052243 WO2014033441A1 (en) 2012-08-27 2013-08-27 Fusion proteins and methods for treating, preventing or ameliorating pain

Publications (2)

Publication Number Publication Date
MX2015002588A true MX2015002588A (es) 2015-09-29
MX369005B MX369005B (es) 2019-10-24

Family

ID=49123869

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015002588A MX369005B (es) 2012-08-27 2013-08-27 Proteinas de fusión y usos de las mismas para tratar, prevenir o aliviar el dolor.

Country Status (18)

Country Link
US (3) US20140056870A1 (es)
EP (2) EP2888359B1 (es)
JP (2) JP2015528461A (es)
KR (1) KR102283218B1 (es)
CN (1) CN104769108A (es)
AU (1) AU2013308233B2 (es)
BR (1) BR112015003947A8 (es)
CA (1) CA2882233A1 (es)
DK (1) DK2888359T3 (es)
ES (2) ES2632470T3 (es)
HK (2) HK1211056A1 (es)
HU (1) HUE035286T2 (es)
MX (1) MX369005B (es)
PL (1) PL2888359T3 (es)
PT (1) PT2888359T (es)
RU (1) RU2652954C2 (es)
UA (1) UA117349C2 (es)
WO (1) WO2014033441A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
US8778634B2 (en) * 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
GB0610867D0 (en) * 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
AU2016310521A1 (en) 2015-08-27 2018-03-01 Massachusetts Institute Of Technology Compositions and methods for treatment of pain
US11186615B2 (en) 2015-10-08 2021-11-30 The Governors Of The University Of Alberta Hepatitis C virus E1/E2 heterodimers and methods of producing same
TW201814045A (zh) 2016-09-16 2018-04-16 英商艾普森生物製藥有限公司 製造雙鏈梭狀芽孢桿菌神經毒素之方法
EP3519430A1 (en) 2016-09-29 2019-08-07 Ipsen Biopharm Limited Hybrid neurotoxins
EP3312290A1 (en) 2016-10-18 2018-04-25 Ipsen Biopharm Limited Cellular vamp cleavage assay
WO2020106962A1 (en) * 2018-11-21 2020-05-28 The Regents Of The University Of Colorado, A Body Corporate Proteins for blocking neurotransmitter release

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
AU7566396A (en) 1995-11-16 1997-06-05 Boehringer Mannheim Gmbh Process for the preparation of peptides by way of streptavidin fusion proteins
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7192596B2 (en) * 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
RU2214420C2 (ru) 1998-05-13 2003-10-20 Биотекон Гезелльшафт Фюр Биотехнологише Энтвиклунг Унд Консультинг Мбх Гибридный белок для ингибирования дегрануляции мастоцитов и его применение
WO2000023573A2 (en) * 1998-10-20 2000-04-27 City Of Hope Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
ES2277854T5 (es) 1999-08-25 2011-02-04 Allergan, Inc. Neurotoxinas recombinantes activables.
US7740868B2 (en) 1999-08-25 2010-06-22 Allergan, Inc. Activatable clostridial toxins
US20080032931A1 (en) 1999-08-25 2008-02-07 Steward Lance E Activatable clostridial toxins
US20090018081A1 (en) 1999-08-25 2009-01-15 Allergan, Inc. Activatable clostridial toxins
ATE261494T1 (de) 1999-12-02 2004-03-15 Health Prot Agency Konstrukte zur verabreichung von therapeutischen wirkstoffen an die neuronzellen
US7138127B1 (en) 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
AU2001270219A1 (en) 2000-06-28 2002-01-08 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals)
CA2433408A1 (en) * 2001-02-23 2002-08-29 Biovitrum Ab Method for purification of soluble ssao
US7049287B2 (en) 2001-10-09 2006-05-23 Synvax, Inc. Nociceptin-based analgesics
CA2475388A1 (en) * 2002-02-14 2003-08-21 William J. Rutter Chimeric molecules for cleavage in a treated host
US20040063912A1 (en) * 2002-03-15 2004-04-01 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
ITMI20022022A1 (it) 2002-09-24 2004-03-25 Girolamo Calo' Analoghi di nocicettina.
GB0228723D0 (en) 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
US20040115727A1 (en) 2002-12-11 2004-06-17 Allergan, Inc., A Corporation Evolved clostridial toxins with altered protease specificity
GB0305149D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Compounds for the treatment of pain
GB0321344D0 (en) * 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
AU2005279741B2 (en) 2004-09-01 2011-10-06 Allergan, Inc. Degradable clostridial toxins
JP4994241B2 (ja) 2004-11-22 2012-08-08 ニューヨーク・ユニバーシティ 遺伝子操作されたクロストリジウム遺伝子、操作された遺伝子によりコードされるタンパク質、およびその使用
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8603779B2 (en) * 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
CA2588292C (en) 2004-12-01 2019-01-15 Health Protection Agency Non-cytotoxic protein conjugates
US8399400B2 (en) * 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
WO2006059093A2 (en) * 2004-12-01 2006-06-08 Health Protection Agency Fusion proteins
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
GB0426397D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US7659092B2 (en) 2004-12-01 2010-02-09 Syntaxin, Ltd. Fusion proteins
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
TWI515007B (zh) * 2006-01-05 2016-01-01 美國猶他大學研究基金會 改善以神經系統為標的之藥劑之性質之方法及組合物
GB0610867D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
EP2038299A2 (en) 2006-07-11 2009-03-25 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
US8993295B2 (en) 2006-07-20 2015-03-31 The General Hospital Corporation Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
AU2008278970A1 (en) * 2007-07-26 2009-01-29 Tibotec Pharmaceuticals Native gp41 assay
WO2009033762A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of endothelin-3 as a therapeutic agent
CN101918021A (zh) 2007-10-23 2010-12-15 阿勒根公司 使用经修饰的梭菌毒素治疗泌尿生殖系统神经疾病的方法
KR20100088683A (ko) 2007-10-23 2010-08-10 알러간, 인코포레이티드 변형 클로스트리듐 독소를 사용한 만성 신경성 염증의 치료 방법
CN102099373A (zh) * 2008-05-22 2011-06-15 百时美施贵宝公司 基于纤连蛋白的多价支架结构域蛋白
US8796216B2 (en) * 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
US8492109B2 (en) 2009-01-20 2013-07-23 Trustees Of Tufts College Methods for the delivery of toxins or enzymatically active portions thereof
PT3281953T (pt) * 2009-03-13 2020-01-15 Allergan Inc Ensaios de base imunológica da actividade de endopeptidase redireccionada
US20100303791A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Glucagon Like Hormone Retargeted Endopepidases
US20100303789A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Neurotrophin Retargeted Endopepidases
US20100303757A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases
US8198229B2 (en) * 2009-05-29 2012-06-12 Allergan, Inc. Methods of treating urogenital-neurological disorders using galanin retargeted endopepidases
MX348567B (es) * 2010-06-04 2017-06-20 Tiumbio Co Ltd Proteina de fusion que tiene actividad de factor vii.
GB201108108D0 (en) * 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins

Also Published As

Publication number Publication date
PT2888359T (pt) 2017-07-14
DK2888359T3 (en) 2017-07-10
RU2015111001A (ru) 2016-10-20
AU2013308233A1 (en) 2015-02-26
EP3246405A1 (en) 2017-11-22
ES2737850T3 (es) 2020-01-16
UA117349C2 (uk) 2018-07-25
EP3246405B1 (en) 2019-04-24
US20150197739A1 (en) 2015-07-16
EP2888359B1 (en) 2017-04-12
US20140056870A1 (en) 2014-02-27
US20190309277A1 (en) 2019-10-10
KR102283218B1 (ko) 2021-07-30
RU2652954C2 (ru) 2018-05-03
ES2632470T3 (es) 2017-09-13
BR112015003947A2 (pt) 2017-08-08
EP2888359A1 (en) 2015-07-01
WO2014033441A1 (en) 2014-03-06
JP2015528461A (ja) 2015-09-28
US11248219B2 (en) 2022-02-15
PL2888359T3 (pl) 2017-09-29
KR20150068353A (ko) 2015-06-19
AU2013308233B2 (en) 2019-05-16
HK1211056A1 (en) 2016-05-13
CN104769108A (zh) 2015-07-08
CA2882233A1 (en) 2014-03-06
HK1245833B (zh) 2020-02-21
JP2019004909A (ja) 2019-01-17
MX369005B (es) 2019-10-24
HUE035286T2 (en) 2018-05-02
BR112015003947A8 (pt) 2018-05-22

Similar Documents

Publication Publication Date Title
MX2015002588A (es) Proteinas de fusion y metodos para tratar, prevenir o aliviar el dolor.
GB0504964D0 (en) Fusion proteins
WO2006059093A3 (en) Fusion proteins
MX2008015227A (es) Tratamiento del dolor.
DK1874807T3 (da) Fusionsproteiner omfattende en ikke-cytotoksisk protease, en targeting-enhed, et protease-spaltningssted og et translokationsdomæne
US9849163B2 (en) Modified non-cytotoxic proteases
IL261432B1 (en) Induced binding proteins and methods of use
PH12016502011A1 (en) Transgene genetic tags and methods of use
US20090035822A1 (en) Fusion Proteins
JP2012518403A5 (es)
AU2005311098A1 (en) Non-cytotoxic protein conjugates
UA112985C2 (uk) Одноланцюговий поліпептидний гібридний білок
CA3111962A1 (en) Clostridial neurotoxins comprising an exogenous activation loop
MX2012005508A (es) Plantas que tienen mejores rasgos relacionados con el rendimiento y un metodo para producirlas.
MX2015017489A (es) Supresion del picor.
SG10201809464RA (en) Antibody gene expression-secretion system
JOP20200285A1 (ar) حمض نووي لعلاج حساسية العث

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: QINETIQ LIMITED.*

FG Grant or registration